Tarsons Products Limited (TARSONS) AI Stock Analysis

• Market Cap: ₹19.11B
• Dividend Yield: 0.54%
• Average Volume (3M): 12.17K
• Price to Earnings (P/E): 69.4
• Beta (1Y): 0.77
• Revenue Growth: 25.22%
• EPS Growth: -25.67%
• Country: IN
• Employees: 823
• Sector: Consumer Goods
• Sector Strength: N/A
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.30
• Shares Outstanding: 53,206,280
• 10 Day Avg. Volume: 29,510
• 30 Day Avg. Volume: 12,167
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹399.00
• Price Target Upside: 11.11% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 59 Neutral
• Price Target: ₹399.00 ▲(11.11% Upside)

The overall score reflects robust financial performance with strong revenue growth but hindered by profitability and free cash flow challenges. Technical indicators suggest a neutral trend, while the high valuation raises concerns about potential overvaluation.

Tarsons Products Limited Business Overview & Revenue Model

Company Description

Tarsons Products Limited (TARSONS) is a prominent Indian company engaged in the manufacturing and distribution of laboratory plasticware. The company operates primarily in the life sciences and healthcare sectors, providing a wide range of laboratory products, including plastic consumables, instruments, and benchtop equipment. Tarsons is known for its high-quality products that cater to scientific research and industrial applications, serving clients across domestic and international markets.

How the Company Makes Money

Tarsons Products Limited generates revenue primarily through the sale of its laboratory plasticware products. The company's key revenue streams include the domestic and international sales of plastic consumables, instruments, and benchtop equipment. Tarsons has established a robust distribution network that facilitates the sale of its products to research institutions, healthcare facilities, and industrial clients. The company's earnings are significantly influenced by its ability to maintain high product quality, expand its product portfolio, and strengthen its market presence through partnerships and collaborations with distributors and research institutions. Additionally, Tarsons invests in research and development to innovate and introduce new products, which can lead to increased sales and profitability.

Tarsons Products Limited Financial Statement Overview

Summary

Tarsons Products Limited shows strong revenue growth and operational efficiency but faces challenges in profitability and free cash flow generation. Moderate leverage and a strong equity base provide financial stability, but liquidity concerns need addressing.

Income Statement

Tarsons Products Limited shows robust revenue growth and improving profitability. The revenue growth rate from 2024 to 2025 was approximately 32.4%, indicating strong business expansion. The gross profit margin in 2025 was about 34.4%, and the net profit margin was 7.6%, which, while positive, suggests room for improvement in cost management. The EBIT margin was 12.3%, and the EBITDA margin was 32.3%, reflecting good operational efficiency. However, the decline in net income from previous years signals some challenges.

Balance Sheet

The company's balance sheet indicates a solid financial structure with a debt-to-equity ratio of 0.54, suggesting moderate leverage. The return on equity for 2025 was 4.7%, which is relatively low, pointing to potential inefficiencies in generating returns for shareholders. The equity ratio of 58.4% indicates a healthy level of financial stability, with a strong equity base.

Cash Flow

Cash flow statements reveal challenges in free cash flow generation, with a negative free cash flow for 2025. The operating cash flow to net income ratio was 3.2, indicating strong cash generation relative to net income. However, the free cash flow to net income ratio was negative, highlighting the need for better capital expenditure management. The company's free cash flow growth rate has been negative over the past year, suggesting potential liquidity concerns.

Breakdown	Mar 2025	Mar 2024	Mar 2022	Mar 2023	Mar 2020
Income Statement
Total Revenue	3.92B	2.96B	2.99B	2.83B	1.75B
Gross Profit	1.35B	2.02B	2.19B	2.18B	1.16B
EBITDA	1.27B	1.11B	1.61B	1.42B	734.06M
Net Income	297.70M	426.40M	1.01B	807.14M	405.31M
Balance Sheet
Total Assets	10.80B	9.72B	5.44B	7.26B	2.49B
Cash, Cash Equivalents and Short-Term Investments	256.52M	226.11M	774.42M	600.23M	253.11M
Total Debt	3.39B	2.69B	216.65M	1.11B	359.24M
Total Liabilities	4.50B	3.59B	543.96M	1.56B	511.37M
Stockholders Equity	6.30B	6.13B	4.90B	5.69B	1.98B
Cash Flow
Free Cash Flow	-550.87M	-816.28M	-485.02M	-1.14B	382.16M
Operating Cash Flow	966.20M	1.03B	834.67M	755.99M	642.16M
Investing Cash Flow	-1.47B	-2.85B	-1.38B	-1.79B	-253.80M
Financing Cash Flow	578.12M	1.36B	1.30B	845.61M	-138.30M

Tarsons Products Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 359.10
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TARSONS, the sentiment is Neutral. The current price of 359.1 is below the 20-day moving average (MA) of 374.16, below the 50-day MA of 378.84, and below the 200-day MA of 377.17, indicating a bearish trend. The MACD of -5.12 indicates Positive momentum. The RSI at 49.44 is Neutral, neither overbought nor oversold. The STOCH value of 35.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:TARSONS.

Tarsons Products Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRMOVER	74 Outperform	₹21.95B	35.48		―	-4.20%	0.92%
STOVEKRAFT	64 Neutral	₹19.73B	48.37		0.42%	6.84%	19.29%
HUHTAMAKI	63 Neutral	₹16.09B	21.60		0.96%	-0.87%	-82.44%
ICEMAKE	60 Neutral	₹11.40B	63.44		0.27%	31.56%	-26.94%
TARSONS	59 Neutral	₹19.11B	69.36		0.54%	25.22%	-25.67%
Sector *	57 Neutral	$3.22B	9.46	-34.32%	2.94%	-25.56%	-353.61%